MinervaX Announces Completion of Enrolment in Phase I Clinical Vaccine Trial as it Addresses the Global Burden of Group B Streptococcus in Older Adults

Posted on by

Full enrolment and dosing commenced with its novel, prophylactic GBS vaccine in both healthy older adults and older adult population with co-morbidities First immunological read-outs are anticipated in Q4, 2023 COPENHAGEN, Denmark, June 27, 2023 /PRNewswire/ — MinervaX ApS, a privately…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.